Do GLP-1 Drugs Like Semaglutide and Liraglutide Cause Suicidal Thoughts? What FDA Reports Show
While semaglutide and liraglutide showed higher-than-expected reports of suicidal ideation in the FDA's adverse event database, no causal link to suicidality was found after accounting for confounding factors.
Quick Facts
What This Study Found
Semaglutide and liraglutide showed disproportionate reporting of suicidal ideation and 'depression/suicidal' events in the FDA Adverse Event Reporting System, with reporting odds ratios whose lower 95% confidence interval exceeded 1.0 (indicating statistical significance).
Critically, no disproportionate reporting of more severe outcomes — suicidal behavior, suicide attempts, or completed suicide — was observed for any FDA-approved GLP-1 receptor agonist. When the data was evaluated using Bradford Hill criteria for causality and confounding factors were considered, the researchers found no causal link between GLP-1 RAs and suicidality.
Key Numbers
How They Did This
Pharmacovigilance analysis using the FDA Adverse Event Reporting System (FAERS) database. Reports from 2005 through October 2023 were analyzed for suicidal ideation, depression/suicidal events, suicidal behavior, suicide attempts, and completed suicide associated with all FDA-approved GLP-1 receptor agonists. Data was compared against other glucose-lowering agents using reporting odds ratios (ROR), with significance defined as the lower 95% CI exceeding 1.0. Bradford Hill criteria were applied to evaluate potential causality.
Why This Research Matters
With tens of millions of people taking semaglutide and liraglutide, even a small increase in suicide risk would be a major public health concern. This analysis of the largest pharmacovigilance database in the world provides reassurance: while suicidal thoughts are reported more frequently with these drugs, the more serious outcomes (attempts and completions) are not elevated, and no causal link was found. This is critical context for the ongoing FDA investigation and for prescribers weighing risks and benefits.
The Bigger Picture
This study is part of the broader pharmacovigilance effort around GLP-1 drugs as their use has exploded for obesity and diabetes. The EMA's initial safety signal triggered worldwide concern, and the FDA launched its own investigation. This FAERS analysis — one of the first systematic evaluations — provides important context showing that the signal is likely driven by reporting bias and confounders (depression is more common in obese and diabetic populations) rather than a true drug effect. It sets the stage for more definitive analyses from clinical trial data and real-world evidence studies.
What This Study Doesn't Tell Us
FAERS is a voluntary reporting system subject to reporting bias, underreporting, and the inability to establish causation. The disproportionate reporting for semaglutide and liraglutide could reflect media attention and the Weber effect (increased reporting for newer, high-profile drugs). The analysis cannot control for all confounders — obesity and diabetes independently increase depression and suicidality risk. Reporting odds ratios measure disproportionality in reporting, not actual risk. The study period predates the massive expansion of GLP-1 use for weight loss in otherwise healthy populations.
Questions This Raises
- ?Will the ongoing FDA investigation using clinical trial data and real-world evidence confirm or contradict these FAERS findings?
- ?Is the elevated reporting of suicidal ideation driven by the Weber effect and media attention rather than a true pharmacological signal?
- ?Should patients with pre-existing depression or suicidal history be screened more carefully before starting GLP-1 drugs?
Trust & Context
- Key Stat:
- No causal link found Despite elevated reports of suicidal ideation with semaglutide and liraglutide, Bradford Hill causality analysis found no evidence these drugs cause suicidality
- Evidence Grade:
- This is a pharmacovigilance (signal detection) study using the FDA's voluntary adverse event reporting database. While it covers a massive dataset, FAERS cannot establish causation, is subject to reporting bias, and lacks the control and rigor of randomized clinical trials. It's valuable for safety signal assessment but not definitive.
- Study Age:
- Published in early 2024, this study is highly timely and directly relevant to the ongoing FDA safety review of GLP-1 drugs and suicidality that was announced in early 2024.
- Original Title:
- The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: reports to the Food and Drug Administration Adverse Event Reporting System (FAERS).
- Published In:
- Expert opinion on drug safety, 23(1), 47-55 (2024)
- Authors:
- McIntyre, Roger S(15), Mansur, Rodrigo B(7), Rosenblat, Joshua D(9), Kwan, Angela T H
- Database ID:
- RPEP-08849
Evidence Hierarchy
Frequently Asked Questions
Should I be worried about suicidal thoughts on Ozempic or Wegovy?
Based on this analysis, the answer is cautiously reassuring. While there were more reports of suicidal thoughts with semaglutide compared to other diabetes drugs, there was no increase in actual suicide attempts or completions, and the researchers found no evidence of a causal link. The higher reporting may reflect media attention and the fact that obesity and diabetes themselves are associated with higher rates of depression. However, if you experience mood changes on any medication, you should talk to your doctor.
What is FAERS and why can't it prove a drug causes side effects?
FAERS (FDA Adverse Event Reporting System) is a database where doctors, patients, and drug companies voluntarily report suspected side effects. It's useful for detecting possible safety signals, but it can't prove causation because: reports are voluntary (some side effects are over- or under-reported), there's no control group for comparison, and many factors besides the drug could explain the reported event. Think of it as a 'tip line' — it flags things worth investigating, but clinical trials are needed to confirm whether a drug actually causes a particular effect.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-08849APA
McIntyre, Roger S; Mansur, Rodrigo B; Rosenblat, Joshua D; Kwan, Angela T H. (2024). The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: reports to the Food and Drug Administration Adverse Event Reporting System (FAERS).. Expert opinion on drug safety, 23(1), 47-55. https://doi.org/10.1080/14740338.2023.2295397
MLA
McIntyre, Roger S, et al. "The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: reports to the Food and Drug Administration Adverse Event Reporting System (FAERS).." Expert opinion on drug safety, 2024. https://doi.org/10.1080/14740338.2023.2295397
RethinkPeptides
RethinkPeptides Research Database. "The association between glucagon-like peptide-1 receptor ago..." RPEP-08849. Retrieved from https://rethinkpeptides.com/research/mcintyre-2024-the-association-between-glucagonlike
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.